Volume | 813,172 |
|
|||||
News | - | ||||||
Day High | 4.57 | Low High |
|||||
Day Low | 4.39 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Inozyme Pharma Inc | INZY | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.57 | 4.39 | 4.57 | 4.39 | 4.51 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,721 | 813,172 | $ 4.46 | $ 3,627,045 | - | 2.689 - 7.795 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:59:42 | 4 | $ 4.4696 | USD |
Inozyme Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
271.18M | 61.77M | - | 0 | -71.17M | -1.15 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Inozyme Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INZY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.11 | 5.11 | 4.38 | 4.67 | 600,518 | -0.66 | -12.92% |
1 Month | 5.85 | 7.795 | 4.38 | 6.09 | 985,511 | -1.40 | -23.93% |
3 Months | 4.72 | 7.795 | 4.38 | 5.97 | 692,785 | -0.27 | -5.72% |
6 Months | 2.88 | 7.795 | 2.689 | 5.12 | 538,762 | 1.57 | 54.51% |
1 Year | 6.14 | 7.795 | 2.689 | 5.19 | 571,422 | -1.69 | -27.52% |
3 Years | 18.79 | 19.58 | 0.991 | 4.64 | 403,237 | -14.34 | -76.32% |
5 Years | 17.93 | 31.6499 | 0.991 | 5.38 | 336,588 | -13.48 | -75.18% |
Inozyme Pharma Description
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. |